In the ever-evolving world of oncology innovation, a bold question is being asked: “Can Targeted Alpha Therapy Cure Cancer?” That’s the headline theme of Tribe Public’s next CEO Presentation and Q&A Webinar, scheduled for Tuesday, April 14, 2026, at 8 a.m. PT / 11 a.m. ET.
A 30-Minute Power Session with NAYA Therapeutics CEO
Known for curating short, focused, and insight-rich sessions, Tribe Public’s events draw institutional and retail investors eager to hear directly from leaders redefining the boundaries of medicine. Tomorrow’s agenda features Daniel Teper, Founder and Chief Executive Officer of NAYA Therapeutics, who will deliver a 20-minute presentation followed by a 5–10-minute live Q&A.
Attendees can submit questions in advance to research@tribepublic.com or drop them directly into the Zoom chat during the session — ensuring that even from behind a screen, participation is anything but passive.
Unlocking Cancer’s “Finish Line”
NAYA Therapeutics is at the forefront of biotechnology’s most promising frontier: Targeted Alpha Therapy (TAT). The company’s therapeutic platform harnesses the rare radioisotope Astatine-211 (²¹¹At)—renowned for its potent alpha emissions and short biological half-life—to attack cancer cells with precision while sparing healthy tissue.
Coupled with NK-cell-engaging bifunctional antibodies, NAYA’s approach is designed to deliver deep, durable cures against aggressive cancers such as hepatocellular carcinoma (HCC) and multiple myeloma. Teper’s mission is straightforward yet profound: give patients not just therapy, but closure—the kind that comes when cancer’s fight is truly finished.
Securing the Critical Supply Chain for Astatine-211
In a field where innovation often collides with logistics, NAYA Therapeutics has taken a strategic step that sets it apart: securing a reliable and scalable supply chain for Astatine-211.
This rare isotope—produced in limited quantities through specialized cyclotron facilities—has historically represented a major bottleneck for companies advancing targeted alpha therapy programs. NAYA’s team recognized early that no breakthrough could succeed without dependable access to this essential ingredient.
To address this, the company established long-term partnerships with high-capacity isotope production sites in North America, providing consistent supply for both preclinical and early clinical programs. This proactive move not only de-risks operational execution but also signals to investors that NAYA is building a foundation for sustainable growth—not just scientific headlines.
As CEO Daniel Teper notes, control of the supply chain isn’t merely a logistical win; it’s a strategic moat. By ensuring consistent isotope availability, NAYA positions itself to accelerate clinical timelines and maintain a competitive advantage as the TAT field matures.
Where Wall Street Meets Science
In a biotech market buzzing with radiopharmaceutical momentum, Targeted Alpha Therapystands out as one of the fastest-growing investment themes. With supply stability now secured and a focus on “finish-line” treatments, NAYA is emerging as a key player poised to transform how advanced cancers are treated—and how investors evaluate innovation risk.
Tribe Public’s 30-minute webinar series continues to bridge the gap between Wall Street insight and breakthrough science, offering investors a front-row seat to what could be the next major inflection point in oncology.
How to Join the Conversation
Registration for tomorrow’s event is open at TribePublic.com. By signing up, participants automatically join Tribe Public’s network, receiving exclusive invitations to future CEO presentations and investor forums.
For more information about NAYA Therapeutics and its pioneering work in targeted alpha therapies, visit www.nayatx.com.
Tomorrow’s event may only last 30 minutes—but given the company’s science, foresight, and supply-chain execution, those 30 minutes may reveal a blueprint for how the next generation of cancer cures gets delivered, atom by atom.
